Evotec SE (ETR:EVT)

Market Cap	920.74M -29.8%
Revenue (ttm)	788.37M -1.1%
Net Income	-103.52M
EPS	-0.58
Shares Out	177.75M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	524,655
Average Volume	849,772
Open	5.35
Previous Close	5.27
Day's Range	5.13 - 5.39
52-Week Range	4.00 - 8.57
Beta	1.30
RSI	50.13
Earnings Date	Aug 13, 2026

About Evotec SE

Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just – Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, immunology, pain and inflammation, infectious, kidney, liver, respiratory, fibrotic and metabolic diseases, and rare diseases. It is also developingcentral nervous system (CNS) and c...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1993
• Employees: 4,467
• Stock Exchange: Deutsche Börse Xetra
• Ticker Symbol: EVT

Financial Performance

In 2025, Evotec SE's revenue was 788.37 million, a decrease of -1.08% compared to the previous year's 796.97 million. Losses were -103.52 million, -47.21% less than in 2024.